公开(公告)号：US20220098318A1

公开(公告)日：2022-03-31

申请号：US17411638

申请日：2021-08-25

Applicant: Genentech, Inc.

Inventor： Raymond D. MENG ,  Robert Wenchen HSIEH ,  Namrata Srivastava PATIL ,  Sean Keith KELLEY ,  Karen Lynn KLING-MILLER ,  William Michael FLANAGAN

IPC: C07K16/28 ,  A61P35/00

Abstract: The invention provides methods of dosing for the treatment of cancers. In particular, provided are methods for treating human patients having cancer, such as a hematologic cancer, by administering a combination of an anti-TIGIT antagonist antibody and an anti-CD20 antibody or anti-CD38 antibody.

公开(公告)号：US20220324981A1

公开(公告)日：2022-10-13

申请号：US17704878

申请日：2022-03-25

Applicant: Genentech, Inc.

Inventor： Raymond D. MENG ,  Namrata Srivastava PATIL ,  William Michael FLANAGAN

IPC: C07K16/28 ,  A61P35/04 ,  C12Q1/6886

Abstract: The invention provides methods of dosing for the treatment of cancers. In particular, provided are methods for treating human patients having lung cancer, such as non-small cell lung cancer (NSCLC), by administering a combination of an anti-TIGIT antagonist antibody and a PD-1 axis binding antagonist.

公开(公告)号：US20230392210A1

公开(公告)日：2023-12-07

申请号：US18062780

申请日：2022-12-07

Applicant: Genentech, Inc.

Inventor： Soren MULLER ,  Barzin Y. NABET ,  Namrata Srivastava PATIL ,  Romain Francois BANCHEREAU

IPC: C12Q1/6886 ,  G01N33/574 ,  G01N33/569 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06

CPC classification number: C12Q1/6886 ,  G01N33/57423 ,  G01N33/56972 ,  C12Q2600/158 ,  A61P35/00 ,  A61K45/06 ,  C12Q2600/106 ,  C07K16/2827

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The compositions and methods described herein can be used, for example, to identify a patient having a cancer who may benefit from treatment with a PD-L1 axis binding antagonist and to treat such patients accordingly. Using the compositions and methods of the disclosure, a patient, such as a human cancer patient, may be determined to be likely to benefit from treatment with a PD-L1 axis binding antagonist if the patient exhibits the presence or an elevated expression level of any of the biomarkers disclosed herein. Exemplary PD-L1 axis binding antagonists that may be used in conjunction with the compositions and methods of the disclosure are PD-L1 binding antagonists, such as anti-PD-L1 antibodies and antigen-binding fragments thereof, including atezolizumab, as well as PD-1 binding antagonists, such as anti-PD-1 antibodies and antigen-binding fragments thereof.